Do Analysts See Any Upside to Revance Therapeutics, Inc. (NASDAQ:RVNC)?

In the most recent trading session, Revance Therapeutics, Inc. (NASDAQ:RVNC) shares saw a move of +1.79%. Covering Wall Street analysts have a consensus target price of $34.60 on the stock. Target predictions might differ vastly from analyst to analyst. This target is applying estimates from analysts polled by Thomson Reuters. 

Sell-side analysts are able to use multiple metrics in order to help calculate target price estimates. A widely used metric is a company’s preice to earnings ratio. This calculation is derived from dividing the current share price by the projected earnings per share. Revance Therapeutics, Inc. currently has a P/E Ratio of N/A. Investors might also evaluate a company’s PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio under one, it may be seen as undervalued. If a company has a PEG Ratio over one, it may represent that the company is overvalued. A PEG Ratio near one may be viewed as fair value. Currently, the company has a PEG Ratio of -0.47.

Looking at stock performance, company shares have recently traded $1.26 away from the 50-day moving average of $15.79 and $1.59 away from the 200-day moving average of $15.46. The stock has been recently noted -57.80% off of the 52-week high of 40.40 and +38.06% off of the 52-week low of 12.35. Monitoring the stock price relative to moving averages and highs and lows for the year may help evaluate the value of the stock in the future.